Cytomegalovirus prevention: Prophylaxis and preemptive therapy

Transplantation

Volumn 84, Issue 6 SUPPL., 2007, Pages

  Humar, Atul ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; VALACICLOVIR; VALGANCICLOVIR;

ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG COST; HUMAN; IMMUNE RESPONSE; INTERMETHOD COMPARISON; MORTALITY; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; VIREMIA;

EID: 34748882368     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000280537.53500.29     Document Type: Conference Paper

References (33)

1. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
2. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: A call to heed the mounting evidence. Clin Infect Dis 2005; 40: 704.
3. Singh N. Optimization of outcomes related to cytomegalovirus in organ transplant recipients. Transplantation 2006; 82:15.
4. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741.
5. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32: 742.
6. Singh N. Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: Are we winning the battle only to lose the war? Eur J Clin Microbiol Infect Dis 2002; 21: 643.
7. Chan KM & Allen SA. Infectious pulmonary complications in lung transplant recipients. Semin Respir Infect 2002; 17: 291.
8. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
9. Doyle AM, Warburton KM, Goral S, et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81: 1106.
10. Freeman RB, Paya C, Pescovitz MD, et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004; 78: 1765.
11. Hoffman La Roche. IMPACT Study: A study of valcyte (valganciclovir) for prevention of cytomegalovirus (CMV) disease in kidney allograft recipients (abstract). Clinical Trials Gov 2006; NT18435.
12. Humar A, Mazzulli T, Moussa G, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005; 5: 1065.
13. Humar A, Paya C, Pescovitz MD, et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 2004; 4: 644.
14. Gamadia LE, Remmerswaal EB, Weel JF, et al. Primary immune responses to human CMV: A critical role for IFN-gamma-producing CD4+T cells in protection against CMV disease. Blood 2003; 101: 2686.
15. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects (abstract). J Exp Med 2005; 202: 673.
16. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005; 5: 1462.
17. Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs 2004; 64: 2763.
18. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
19. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006; 71: 154.
20. Ayala E, Greene J, Sandin R, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 851.
21. Singh N, Wannstedt C, Keyes L, et al. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79: 85.
22. van der Heiden PL, Kalpoe JS, Barge RM, et al. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalo virus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006; 37: 693.
23. Humar A, Siegal D, Moussa G, et al. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 2005; 192: 1154.
24. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106.
25. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645.
26. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189: 1615.
27. Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir- resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002; 21: 1274.
28. Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185: 20.
29. Singh N & Wagener MM. Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2006; 144:456.
30. Cytomegalovirus. Am J Transplant 2004; 4(Suppl 10): 51.
31. Chong AS, Zeng H, Knight DA, et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant 2006; 6: 69.
32. Arvin AM, Fast P, Myers M, et al. Vaccine development to prevent cytomegalovirus disease: Report from the National Vaccine Advisory Committee. Clin Infect Dis 2004; 39: 233.
33. Schleiss M. Progress in cytomegalovirus vaccine development. Herpes 2005; 12: 66.